Preservation of Cellular Therapies

Currently 1.2 million patients are receiving treatment from regenerative medicine products produced by 171 companies with a capital value of ~$4.7 billion.  Most molecules, cells and tissues are collected at a given time and location for use at a later time. Therefore, our ability to stabilize biological properties (e.g. viability, biomarkers) during transportation and long-term storage is a critical technology.

The preservation of cellular therapies is the central focus of this professional short course. Come learn about fundamentals of preservation, protocol development, design of a storage facility, regulatory issues associated with preservation of cell therapies, clinical issues and more.